proxyvotesnow.com

Home › Companies › COHERUS BIOSCIENCES INC. › 2023-2024

COHERUS BIOSCIENCES INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and COHERUS BIOSCIENCES INC.’s Form 8-K, filed 2024-06-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 6Ballot items
  • 148Asset managers
  • 874Fund votes
  • 2024-05-29Meeting date

Proxy season: 2023-2024 2024-2025

Explore COHERUS BIOSCIENCES INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by COHERUS BIOSCIENCES INC.

These tallies are COHERUS BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

COHERUS BIOSCIENCES INC. — official shareholder meeting results, meeting held 2024-05-29
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Lee N. Newcomer, MD 48,281,843---- 10,274,659-- Majority: yes
Elect Director: Charles W. Newton 47,197,934---- 11,358,568-- Majority: yes
Elect Director: Kimberly J. Tzoumakas 46,098,866---- 12,457,636-- Majority: yes
Proposal 2. The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. 79,827,737551,990147,169 --0 Majority: yes
Proposal 3. The Company's stockholders approved a non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote). 40,280,18216,457,0461,819,274 --21,970,394 Majority: yes
Proposal 4. The Company's stockholders approved the amendment and restatement of the Company's 2014 Equity Incentive Award Plan. 37,628,12318,905,8812,022,498 --21,970,394 Majority: yes

Source: COHERUS BIOSCIENCES INC., Form 8-K, filed with the SEC on 2024-06-04 — read the filing on EDGAR.

How asset managers voted at the COHERUS BIOSCIENCES INC. 2023-2024 meeting

Each item below shows how the 148 asset managers that disclosed a COHERUS BIOSCIENCES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To vote on a non-binding, advisory basis to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 16 wordings of this item as funds reported it.

71% Majority: yes · of votes cast

FOR 71%AGAINST 29%
FOR: 40,280,182AGAINST: 16,457,046

COHERUS BIOSCIENCES INC.’s own tally for this item (“Proposal 3. The Company's stockholders approved a non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).”): 40,280,182 for, 16,457,046 against, per its Form 8-K filed 2024-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,725,740 outstanding shares: 35% for, 14% against (49.5% of the company cast a for/against vote).

The 142 asset managers below cast 74% of the shares they voted on this item FOR (32,891,768 for, 11,764,309 against).

FOR 74%AGAINST 26%
FOR: 32,891,768 (73.6%)AGAINST: 11,764,309 (26.3%)ABSTAIN: 29,534 (0.1%)
Largest asset managers voting on “To vote on a non-binding, advisory basis to approve the compensation of the Company's named executive officers” at COHERUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Rubric Capital Management LP08,307,399 00Against
Temasek Holdings (Private) Ltd7,381,1160 00For
Vanguard6,172,9870 00For
BlackRock3,736,444776 00For
C WorldWide Asset Management Fondsmaeglerselskab A/S01,928,464 00Against
Charles Schwab1,511,7940 00For
Kohlberg Kravis Roberts & Co. L.P.1,499,4990 00For
State Street1,080,409368 00For
DISCIPLINED GROWTH INVESTORS INC /MN01,068,751 00Against
MUTUAL FUND SERIES TRUST1,000,0000 00For
Delaware/Macquarie900,0000 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST900,0000 00For
Citadel831,5930 00For
Clearline Capital LP784,4490 00For
PEREGRINE CAPITAL MANAGEMENT LLC772,3410 00For
Woodline Partners LP684,9480 00For
Northern Trust525,92554 00For
Two Sigma498,0320 00For
Hudson Bay Capital Management LP496,5730 00For
Lazard387,7000 00For
MELLON INVESTMENTS Corp326,4790 00For
Wellington305,8790 00For
SEI303,62776 00For
Birchview Capital, LP256,0000 00For
Goldman Sachs194,0380 00For

Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.

2. To approve the amendment and restatement of the Company's 2014 Equity Incentive Award Plan (the "2014 Plan").

COMPENSATIONMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

67% Majority: yes · of votes cast

FOR 67%AGAINST 33%
FOR: 37,628,123AGAINST: 18,905,881

COHERUS BIOSCIENCES INC.’s own tally for this item (“Proposal 4. The Company's stockholders approved the amendment and restatement of the Company's 2014 Equity Incentive Award Plan.”): 37,628,123 for, 18,905,881 against, per its Form 8-K filed 2024-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,725,740 outstanding shares: 33% for, 16% against (49.3% of the company cast a for/against vote).

The 42 asset managers below cast 84% of the shares they voted on this item FOR (9,596,383 for, 1,847,396 against).

FOR 84%AGAINST 16%
FOR: 9,596,383 (83.6%)AGAINST: 1,847,396 (16.1%)ABSTAIN: 29,534 (0.3%)
Largest asset managers voting on “To approve the amendment and restatement of the Company's 2014 Equity Incentive Award Plan (the "2014 Plan").” at COHERUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,847,3130 00For
BlackRock1,605,5510 00For
MUTUAL FUND SERIES TRUST1,000,0000 00For
Delaware/Macquarie0900,000 00Against
Charles Schwab689,4560 00For
BRIDGEWAY FUNDS INC0168,000 00Against
Equitable17,503146,500 00Against
New York Life0154,248 00Against
SEI151,6200 00For
QUANTITATIVE MASTER SERIES LLC125,8580 00For
Fidelity91,73919,178 00For
MFS098,019 00Against
Lincoln Financial083,905 00Against
Northern Trust065,347 00Against
John Hancock038,068 00Against
Pacific Life33,8800 00For
Transamerica031,088 00Against
Brighthouse01 29,5340Abstain
ProShares026,494 00Against
Bridge Builder Trust23,3910 00For
Principal Exchange-Traded Funds014,995 00Against
DWS014,337 00Against
Principal014,075 00Against
Victory Capital013,979 00Against
AIG/SunAmerica013,430 00Against

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

3. To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 79,827,737AGAINST: 551,990

COHERUS BIOSCIENCES INC.’s own tally for this item (“Proposal 2. The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.”): 79,827,737 for, 551,990 against, per its Form 8-K filed 2024-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,725,740 outstanding shares: 70% for, 0.5% against (70% of the company cast a for/against vote).

The 42 asset managers below cast 99.9% of the shares they voted on this item FOR (11,444,695 for, 310 against).

FOR 99.7%
FOR: 11,444,695 (99.7%)AGAINST: 310 (0.0%)ABSTAIN: 29,534 (0.3%)
Largest asset managers voting on “To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young LLP as our indepen” at COHERUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,847,3130 00For
BlackRock1,605,5510 00For
MUTUAL FUND SERIES TRUST1,000,0000 00For
Delaware/Macquarie900,0000 00For
Charles Schwab689,4560 00For
BRIDGEWAY FUNDS INC168,0000 00For
Equitable164,0030 00For
New York Life154,2480 00For
SEI151,6200 00For
QUANTITATIVE MASTER SERIES LLC125,8580 00For
Fidelity110,9170 00For
MFS98,0190 00For
Lincoln Financial83,9050 00For
Northern Trust65,3470 00For
John Hancock38,0680 00For
Pacific Life33,8800 00For
Transamerica31,0880 00For
Brighthouse10 29,5340Abstain
ProShares26,4940 00For
Bridge Builder Trust23,3910 00For
Principal Exchange-Traded Funds14,9950 00For
DWS14,3370 00For
Principal14,0750 00For
Victory Capital13,9790 00For
AIG/SunAmerica13,4300 00For

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

4. To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Charles W. Newton

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD 19%
FOR: 47,197,934WITHHELD: 11,358,568

COHERUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Charles W. Newton”): 47,197,934 for, 11,358,568 withheld, per its Form 8-K filed 2024-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,725,740 outstanding shares: 41% for, 10% withheld (51.0% of the company cast a for/withheld vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (10,337,275 for, 0 against).

FOR 99%
FOR: 10,337,275 (98.7%)ABSTAIN: 137,264 (1.3%)
Largest asset managers voting on “To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their s” at COHERUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,847,3130 00For
BlackRock1,605,5510 00For
Delaware/Macquarie900,0000 00For
Charles Schwab689,4560 00For
BRIDGEWAY FUNDS INC168,0000 00For
Equitable164,0030 00For
New York Life154,2480 00For
SEI151,6200 00For
QUANTITATIVE MASTER SERIES LLC125,8580 00For
Fidelity110,9170 00For
MFS98,0190 00For
Lincoln Financial00 83,9050Abstain
Northern Trust65,3470 00For
John Hancock38,0680 00For
Pacific Life33,8800 00For
Transamerica31,0880 00For
Brighthouse10 29,5340Abstain
ProShares26,4940 00For
Bridge Builder Trust23,3910 00For
Principal Exchange-Traded Funds14,9950 00For
DWS14,3370 00For
Principal14,0750 00For
Victory Capital13,9790 00For
AIG/SunAmerica13,4300 00For
Voya12,0750 00For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

5. To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Kimberly J. Tzoumakas

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD 21%
FOR: 46,098,866WITHHELD: 12,457,636

COHERUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Kimberly J. Tzoumakas”): 46,098,866 for, 12,457,636 withheld, per its Form 8-K filed 2024-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,725,740 outstanding shares: 40% for, 11% withheld (51.0% of the company cast a for/withheld vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (10,120,373 for, 0 against).

FOR 97%
FOR: 10,120,373 (96.6%)ABSTAIN: 354,166 (3.4%)
Largest asset managers voting on “To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their s” at COHERUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,847,3130 00For
BlackRock1,605,5510 00For
Delaware/Macquarie900,0000 00For
Charles Schwab689,4560 00For
BRIDGEWAY FUNDS INC00 168,0000Abstain
Equitable17,5030 146,5000Abstain
New York Life154,2480 00For
SEI151,6200 00For
QUANTITATIVE MASTER SERIES LLC125,8580 00For
Fidelity110,9170 00For
MFS98,0190 00For
Lincoln Financial83,9050 00For
Northern Trust65,3470 00For
John Hancock38,0680 00For
Pacific Life33,8800 00For
Transamerica31,0880 00For
Brighthouse10 29,5340Abstain
ProShares26,4940 00For
Bridge Builder Trust23,3910 00For
Principal Exchange-Traded Funds14,9950 00For
DWS14,3370 00For
Principal14,0750 00For
Victory Capital13,9790 00For
AIG/SunAmerica13,4300 00For
Voya12,0750 00For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

6. To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Lee N. Newcomer, MD

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD 18%
FOR: 48,281,843WITHHELD: 10,274,659

COHERUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Lee N. Newcomer, MD”): 48,281,843 for, 10,274,659 withheld, per its Form 8-K filed 2024-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,725,740 outstanding shares: 42% for, 9% withheld (51.0% of the company cast a for/withheld vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (10,434,876 for, 0 against).

FOR 99.6%
FOR: 10,434,876 (99.6%)ABSTAIN: 39,663 (0.4%)
Largest asset managers voting on “To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their s” at COHERUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,847,3130 00For
BlackRock1,605,5510 00For
Delaware/Macquarie900,0000 00For
Charles Schwab689,4560 00For
BRIDGEWAY FUNDS INC168,0000 00For
Equitable164,0030 00For
New York Life154,2480 00For
SEI151,6200 00For
QUANTITATIVE MASTER SERIES LLC125,8580 00For
Fidelity110,9170 00For
MFS98,0190 00For
Lincoln Financial83,9050 00For
Northern Trust65,3470 00For
John Hancock38,0680 00For
Pacific Life33,8800 00For
Transamerica31,0880 00For
Brighthouse10 29,5340Abstain
ProShares26,4940 00For
Bridge Builder Trust23,3910 00For
Principal Exchange-Traded Funds14,9950 00For
DWS14,3370 00For
Principal14,0750 00For
Victory Capital13,9790 00For
AIG/SunAmerica13,4300 00For
Voya12,0750 00For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

Largest COHERUS BIOSCIENCES INC. shareholders voting in 2023-2024

Ranked by the number of COHERUS BIOSCIENCES INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 114,725,740 shares outstanding at the time of that meeting.

Top COHERUS BIOSCIENCES INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1Rubric Capital Management LP 7.24%
2Temasek Holdings (Private) Ltd 6.43%
3Vanguard 5.38%
4BlackRock 3.26%
5C WorldWide Asset Management Fondsmaeglerselskab A/S 1.68%
6Charles Schwab 1.32%
7Kohlberg Kravis Roberts & Co. L.P. 1.31%
8State Street 0.94%
9DISCIPLINED GROWTH INVESTORS INC /MN 0.93%
10MUTUAL FUND SERIES TRUST 0.87%

Reported COHERUS BIOSCIENCES INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

COHERUS BIOSCIENCES INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
BlackRock 9.12% 13F
Vanguard Group 9.00% 13F
Entities associated with Temasek Holdings (Private) Limited 6.43% DEF14A
Ali J. Satvat 2.65% DEF14A
Citadel Advisors 2.50% 13F
Geode Capital 1.92% 13F
State Street 1.74% 13F
Two Sigma 1.27% 13F
Millennium Management 1.10% 13F
Dennis M. Lanfear 1.07% DEF14A

Percentages above are of 114,725,740 shares outstanding, as reported by COHERUS BIOSCIENCES INC. on its Form 10-Q dated 2024-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from COHERUS BIOSCIENCES INC.’s 10-Q dated 2024-04-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At COHERUS BIOSCIENCES INC.'s shareholder meeting held 2024-05-29, in the 2023-2024 proxy season, 148 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 874 separate fund positions. On the most widely held item on that ballot — To vote on a non-binding, advisory basis to approve the compensation of the Company's named… — FOR was 71% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: COHERUS BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-04.

COHERUS BIOSCIENCES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.